Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) posted its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.03), reports. Foamix Pharmaceuticals had a negative return on equity of 39.20% and a negative net margin of 823.74%. The company had revenue of $0.90 million for the quarter, compared to the consensus estimate of $0.90 million. During the same quarter in the previous year, the firm posted ($0.19) EPS. The business’s revenue for the quarter was down 64.6% compared to the same quarter last year.

Shares of Foamix Pharmaceuticals (NASDAQ:FOMX) traded down $0.01 during trading hours on Thursday, reaching $5.47. 75,527 shares of the company’s stock traded hands, compared to its average volume of 165,253. Foamix Pharmaceuticals has a 1 year low of $4.03 and a 1 year high of $11.27.

FOMX has been the topic of several research reports. Zacks Investment Research downgraded shares of Foamix Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd. HC Wainwright started coverage on shares of Foamix Pharmaceuticals in a research report on Thursday, August 24th. They issued a “buy” rating and a $12.00 price target on the stock. Finally, Credit Suisse Group restated a “buy” rating and issued a $9.00 price target on shares of Foamix Pharmaceuticals in a research report on Wednesday, July 19th.

TRADEMARK VIOLATION NOTICE: This article was posted by Watch List News and is the property of of Watch List News. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at

About Foamix Pharmaceuticals

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.

Earnings History for Foamix Pharmaceuticals (NASDAQ:FOMX)

Receive News & Ratings for Foamix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.